News | August 13, 2021
Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
EPS at Rs 32.19
Substantial reduction in losses
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The aim is to create new genomics solutions that could combat cancer and advance market access
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Nearly 6,000 patients have been treated with the drug since 2017
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
